Canagliflozin
- Generic Name
- Canagliflozin
- Brand Names
- Invokamet, Invokana
- Drug Type
- Small Molecule
- Chemical Formula
- C24H25FO5S
- CAS Number
- 842133-18-0
- Unique Ingredient Identifier
- 6S49DGR869
- Background
Canagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise .
...
- Indication
This drug is used in conjunction with diet and exercise to increase glycemic control in adults diagnosed with type 2 diabetes mellitus .
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Major Adverse Cardiac Events, Type 2 Diabetes Mellitus, Doubling of serum creatinine
- Associated Therapies
- -
Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT05090358
- Locations
- 🇺🇸
Ohio State University (Data Collection & Data Analysis), Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2021-03-12
- Target Recruit Count
- 1167
- Registration Number
- NCT04796428
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
- Conditions
- Interventions
- First Posted Date
- 2020-03-11
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT04304261
- Locations
- 🇨🇳
Zhiming Zhu, Chongqing, Chongqing, China
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04014192
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Replication of the CANVAS Diabetes Trial in Healthcare Claims
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 152202
- Registration Number
- NCT03936010
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 714582
- Registration Number
- NCT03492580
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 308
- Registration Number
- NCT03436693
- Locations
- 🇯🇵
Research site, Yamaguchi, Japan
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 25358
- Registration Number
- NCT03249506
- Locations
- 🇺🇸
Health ResearchTx, LLC, Trevose, Pennsylvania, United States
Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 788
- Registration Number
- NCT03136484
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 34
- Registration Number
- NCT02964585
- Locations
- 🇺🇸
The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.